Cell Cycle Dysregulation Influences Survival in High Risk Breast Cancer Patients

REFERENCES

• Sherr C. J. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res. 2000; 60: 3689–3695
   PubMed Web of Science ®Google Scholar
• Tassan J. P., Schultz S. J., Bartek J., Nigg E. A. Cell cycle analysis of the activity, subcellular localization, and subunit composition of human CAK (CDK-activating kinase). J. Cell. Biol. 1994; 127: 467–478
   PubMed Web of Science ®Google Scholar
• Morgan D. O. Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu. Rev. Cell. Dev. Biol. 1997; 13: 261–291
   Google Scholar
• Buolamwini J. K. Cell cycle molecular targets in novel anticancer drug discovery. Curr. Pharm. Des. 2000; 6(4)379–392
   PubMed Web of Science ®Google Scholar
• Solomon M. J. Activation of the various cyclin/cdc2 protein kinases. Curr. Opin. Cell. Biol. 1993; 5(2)180–186
   PubMed Web of Science ®Google Scholar
• Foster J. S., Henley D. C., Bukovsky A., Seth P., Wimalasena J. Multifaceted regulation of cell cycle progression by estrogen: regulation of Cdk inhibitors and Cdc25A independent of cyclin D1-Cdk4 function. Mol. Cell. Biol. 2001; 21(3)794–810
   PubMed Web of Science ®Google Scholar
• Weinberg R. A. The retinoblastoma protein and cell cycle control. Cell. 1995; 81(3)323–330
   PubMed Web of Science ®Google Scholar
• Yang J., Kornbluth S. All aboard the cyclin train: subcellular trafficking of cyclins and their CDK partners. Trends Cell. Biol. 1999; 9(6)207–210
   PubMed Web of Science ®Google Scholar
• Sherr C. J., Roberts J. M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999; 13(1112)1501–1512
   PubMedGoogle Scholar
• Sherr C. J., Roberts J. M. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 1995; 9(10)1149–1163
   PubMed Web of Science ®Google Scholar
• Pines J. Cyclins and cyclin-dependent kinases: theme and variations. Adv. Cancer Res. 1995; 66: 181–212
   PubMedGoogle Scholar
• Grana X., Reddy E. P. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene. 1995; 11(2)211–219
   PubMed Web of Science ®Google Scholar
• Goldhirsch A., Glick J. H., Gelber R. D., Coates A. S., Thurlimann B, Senn H. J. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann. Oncol. 2005; 16(10)1569–1583
   PubMed Web of Science ®Google Scholar
• Remmele W., Stegner H. E. [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. Pathologe. 1987; 8(3)138–140
   PubMed Web of Science ®Google Scholar
• Barbareschi M, van Tinteren H, Mauri F. A., Veronese S, Peterse H, Maisonneuve P, Caffo O, Scaioli M, Doglioni C, Galligioni E, Dalla Palma P, Michalides R. p27(kip1) expression in breast carcinomas: an immunohistochemical study on 512 patients with long-term follow-up. Int. J. Cancer. 2000; 89(3)236–241
   PubMed Web of Science ®Google Scholar
• Pohl G, Rudas M, Dietze O, Lax S, Markis E, Pirker R, Zielinski C. C., Hausmaninger H, Kubista E, Samonigg H, Jakesz R, Filipits M. High p27Kip1 expression predicts superior relapse-free and overall survival for premenopausal women with early-stage breast cancer receiving adjuvant treatment with tamoxifen plus goserelin. J. Clin. Oncol. 2003; 21(19)3594–3600
   PubMed Web of Science ®Google Scholar
• Bast R. C., Jr., Ravdin P., Hayes D. F., Bates S., Fritsche H., Jr., Jessup J. M., Kemeny N, Locker G. Y., Mennel R. G., Somerfield M. R. American Society of Clinical Oncology Tumor Markers Expert Panel. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J. Clin. Oncol. 2001; 19(6)1865–1878
   PubMed Web of Science ®Google Scholar
• Duffy M. J. Predictive markers in breast and other cancers: a review. Clin. Chem. 2005; 51(3)494–503
   PubMed Web of Science ®Google Scholar
• Beresford M. J., Wilson G. D., Makris A. Measuring proliferation in breast cancer: practicalities and applications. Breast Cancer Res. 2006; 8(6)216
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365(9472)1687–1717
   PubMed Web of Science ®Google Scholar
• Bernards R., Weinberg R. A. A progression puzzle. Nature 2002; 418(6900)823
   PubMed Web of Science ®Google Scholar
• Barnes A, Pinder S E, Bell J A, Paish E. C., Wencyk P. M., Robertson J. F., Elston C. W., Ellis I. O. Expression of p27kip1 in breast cancer and its prognostic significance. J. Pathol. 2003; 201(3)451–459
   PubMed Web of Science ®Google Scholar
• Li Y, Pan J, Li J. L., Lee J. H., Tunkey C, Saraf K, Garbe J. C., Whitley M. Z., Jelinsky S. A., Stampfer M. R., Haney S. A. Transcriptional changes associated with breast cancer occur as normal human mammary epithelial cells overcome senescence barriers and become immortalized. Mol. Cancer. 2007; 6: 7
   PubMed Web of Science ®Google Scholar
• Li Z, Jiao X, Wang C, Ju X, Lu Y, Yuan L, Lisanti M. P., Katiyar S, Pestell R. G. Cyclin D1 induction of cellular migration requires p27(KIP1). Cancer Res. 2006; 66(20)9986–9994
   PubMed Web of Science ®Google Scholar
• Nass S. J., Dickson R. B. Epidermal growth factor-dependent cell cycle progression is altered in mammary epithelial cells that overexpress c-myc. Clin. Cancer Res. 1998; 4(7)1813–1822
   PubMed Web of Science ®Google Scholar
• Han S, Ahn S. H., Park K, Bae B. N., Kim K. H., Kim H. J., Kim Y. D., Kim H. Y. P16INK4a protein expression is associated with poor survival of the breast cancer patients after CMF chemotherapy. Breast Cancer Res. Treat. 2001; 70(3)205–212
   PubMed Web of Science ®Google Scholar
• Kuhling H, Alm P, Olsson H, Fernö M, Baldetorp B, Parwaresch R, Rudolph P. Expression of cyclins E, A, and B, and prognosis in lymph node-negative breast cancer. J. Pathol. 2003; 199: 424–431
   PubMed Web of Science ®Google Scholar
• Poikonen P, Sjostrom J, Amini R. M., Villman K, Ahlgren J, Blomqvist C., Cyclin A. As a marker for prognosis and chemotherapy response in advanced breast cancer. Br. J. Cancer. 2005; 93(5)515–519
   PubMed Web of Science ®Google Scholar
• Bukholm I. R., Bukholm G, Nesland J. M. Over-expression of cyclin A is highly associated with early relapse and reduced survival in patients with primary breast carcinomas. Int. J. Cancer. 2001; 93(2)283–287
   PubMed Web of Science ®Google Scholar
• Porter P. L., Barlow W. E., Yeh I. T., Lin M. G., Yuan X. P., Donato E, Sledge G. W., Shapiro C L, Ingle J. N., Haskell C. M., Albain K. S., Roberts J. M., Livingston R. B., Hayes D. F. p27(Kip1) and cyclin E expression and breast cancer survival after treatment with adjuvant chemotherapy. J. Natl. Cancer Inst. 2006; 98(23)1723–1731
   PubMed Web of Science ®Google Scholar
• Jacobs T. W., Prioleau J. E., Stillman I. E., Schnitt S. J. Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer. J. Natl Cancer Inst. 1996; 88(15)1054–1059
   PubMed Web of Science ®Google Scholar